Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13

Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatologyWIN027 blocks 2 well-validated and synergistic drivers of inflammation — TSLP and IL‑13 — that play integral roles in respiratory and dermatology diseasesWIN027 deepens the company’s immunology pipeline and is currently in Phase 1 BASEL, Switzerland, Dec. 21, 2025 (GLOBE NEWSWIRE) -- Windward Bio AG, a private, clinical-sta ...